Details

Autor(en) / Beteiligte

• de Oliveira, Alane Cabral
• Hillard, Elizabeth A.
• Pigeon, Pascal
• Rocha, Danilo Damasceno
• Rodrigues, Felipe A.R.
• Montenegro, Raquel C.
• Costa-Lotufo, Letícia V.
• Goulart, Marilia O.F.
• Jaouen, Gérard

Titel

Biological evaluation of twenty-eight ferrocenyl tetrasubstituted olefins: Cancer cell growth inhibition, ROS production and hemolytic activity

Ist Teil von

• European journal of medicinal chemistry, 2011-09, Vol.46 (9), p.3778-3787

Ort / Verlag

Kidlington: Elsevier Masson SAS

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• The antiproliferative effects of twenty-eight tetrasubstituted olefins bearing a ferrocenyl group, including six never-reported compounds, were evaluated against SF-295 (human glioblastoma), HCT-8 (human colon cancer), MDA-MB-435 (human melanoma) and HL-60 (human promyelocytic leukemia) using the MTT test. IC 50 values were determined for twenty-three active compounds and of these, ten compounds had IC 50 values lower than 2 μM on one or more cell lines. Of all the compounds, only two produced significant amounts of ROS on HL-60 cells, and ROS production and growth inhibition could not be correlated. The ten most antiproliferative compounds were tested for their hemolytic activity on mouse erythrocytes. Five compounds showing high antiproliferative activity and low hemolytic activity were thus identified for further study. [Display omitted] ► Ferrocene compounds show low micromolar activity against cancer cells. ► Aminated ether substituents contribute to activity, but also to hemolysis. ► ROS production in HL-60 does not correlate with activity. ► MDA-MB-435 melanoma cells are resistant to most ferrocenyl compounds.